Pharmaceuticals

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring

Pharmaceuticals Recent News

New Legalization Law In Germany Creates Broader Liberties For Pharmacists
The news was trumpeted around the world: Germany, the European Union’s largest economy, surprised the global cannabis industry with the announcement of the legalization of cannabis for restricted recreational use, to be effective April 1.
Pfizer's Mixed Bag: A Look At The Fourth Quarter 2023 Earnings Call - Main Takeaways
Pfizer Inc. (NYSE: PFE) recently held its fourth-quarter earnings call, revealing a year of contrasts for the pharmaceutical giant. While the company faced setbacks, particularly with its COVID-19 products, it also made significant strides in other areas, setting a foundation for future growth.
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to charges that resulted from a
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Short Seller's Bombshell Report Rattles Grifols: Stock Chart Points To Potential Further Decline
Grifols, the Spanish multinational pharmaceutical titan involved into blood-related medicines, saw its shares fall by 24% on Tuesday.
Healthcare Champions Kick Off 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026. Merck & CO Inc (NYSE:
QuantumScape, Peloton, Eli Lilly, Walgreens, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34.
Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines
Eli Lilly announced a new website allowing patients to get a weight loss drug prescription through a telehealth provider, with disease management resources, home delivery of medicines.
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy NASDAQ faced a downturn, falling 1.63% to 14,765.94. Similarly, the S&P 500 also witnessed a decline, dropping 0.57% to 4,742.83.
Mark Cuban's Cost Plus Drugs Gets Medication Elon Musk Asked About 6 Months Ago: 'Still Ready To Save Tesla, SpaceX And X a F**kton of Money'
Cuban updated Musk, sharing a link to purchase Ivermectin on Cost Plus Drugs' website.
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this 
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the 
Perrigo Cuts Annual Guidance, This OTC Drug Firm Also Reports Mixed Q3 Earnings
Perrigo Company PLC (NYSE: PRGO) reported 
Why Is Alpine Immune Sciences Stock Trading Higher Today?
Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology 
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries.
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market. 
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical and medical devices businesses.
Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival
Clene Inc. (NASDAQ: CLNN) released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the 
Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids
Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention
Estrella Immunopharma Nears Completion Of SPAC Listing
Key Takeaways: Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China’s UP Fintech The cancer therapy developer was only founded last year, but thinks it can start generating revenue as soon as 2025 using proprietary technology from its founder By Doug Young